Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SB17170 in advanced solid tumors
NCT05522868Phase 1Recruiting
- Sponsor
- SPARK Biopharma
- Start
- Oct 2022
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of SB17170 in solid tumor (3 cohorts), sponsored by SPARK Biopharma. Primary endpoint: Safety and tolerability of SB17170 at 21 days. Started Oct 2022; status: recruiting.
02
Drugs
SB17170
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05522868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05522868.